Diff-Quik细胞学涂片用于肺癌大面板突变检测:预测DNA含量及低恶性细胞样本的成功率
各显微镜参数均显著影响DNA产量,算法预测>50 ng DNA产量的AUC为0.86;50个样本(89%)测序成功,低恶性细胞含量(<25%)和涂片面积(<15%)是失败主因。所有标准治疗突变在重复涂片中均检出,两例标准样本不足者发现Tier 1/2突变,涂片可评估肿瘤突变负荷。
要点
- Diff-Quik涂片显微镜评估可预测DNA产量,AUC达0.86。
- 低恶性细胞含量(<25%)和涂片面积(<15%)是测序失败主因。
- 涂片可用于大面板测序并评估肿瘤突变负荷。
核心结论
- Diff-Quik涂片显微镜评估可分流样本用于全面面板测序,是细胞块传统检测的优良替代。
研究设计与样本
- 前瞻性研究纳入66例EBUS TBNA恶性淋巴结患者,收集Diff-Quik涂片和细胞块。
- 对27例患者的56张涂片行TruSight Oncology 500测序。
主要发现
- 每个显微镜参数均显著影响DNA产量。
- 算法预测涂片>50 ng DNA产量的AUC为0.86。
- 50个DNA样本(89%)测序成功,恶性细胞含量不一。
- 低恶性细胞含量(<25%)和涂片面积(<15%)是失败主因。
- 所有标准治疗突变在重复涂片中均检出,两例标准样本不足者发现Tier 1/2突变。
关键数值与推荐
- 预测>50 ng DNA产量的AUC为0.86。
- 测序成功率89%(50/56)。
- 失败相关因素:恶性细胞含量<25%和涂片面积<15%。
临床怎么用
- Diff-Quik涂片可显微镜评估后分流用于大面板测序。
- 低恶性细胞含量和涂片面积小时需注意测序失败风险。
- 涂片可作为细胞块检测的替代,尤其标准样本不足时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cytology smears are commonly collected during endobronchial ultrasound-guided transbronchial needle aspiration (EBUS TBNA) procedures but are rarely used for molecular testing. Studies are needed to demonstrate their great potential, in particular for the prediction of malignant cell DNA content and for utility in molecular diagnostics using large gene panels. METHODS: A prospective study was performed on samples from 66 patients with malignant lymph nodes who underwent EBUS TBNA. All patients had air-dried, Diff-Quik cytology smears and formalin-fixed, paraffin-embedded cell blocks collected for cytopathology and molecular testing. One hundred eighty-five smears were evaluated by microscopy to estimate malignant cell percentage and abundance and to calculate smear size and were subjected to DNA extraction. DNA from 56 smears from 27 patients was sequenced with the TruSight Oncology 500 assay (Illumina). RESULTS: Each microscopy parameter had a significant effect on the DNA yield. An algorithm was developed that predicted a >50-ng DNA yield of a smear with an area under the curve of 0.86. Fifty DNA samples (89%) with varying malignant yields were successfully sequenced. Low-malignant-cell content (<25%) and smear area (<15%) were the main reasons for failure. All standard-of-care mutations were detected in replicate smears from individual patients, regardless of malignant cell content. Tier 1/2 mutations were discovered in two cases where standard-of-care specimens were inadequate for sequencing. Smears were scored for tumor mutation burden. CONCLUSIONS: Microscopy of Diff-Quik smears can triage samples for comprehensive panel sequencing, which highlights smears as an excellent alternative to traditional testing with cell blocks.
引用
- Fielding DI, Dalley AJ, Singh M, et al. Evaluating Diff-Quik cytology smears for large-panel mutation testing in lung cancer-Predicting DNA content and success with low-malignant-cellularity samples. Cancer Cytopathol. 2023. PMID: 36938641. doi:10.1002/cncy.22690
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。